On the other hand, if the test had suboptimal specificity between degenerative and non-degenerative parkinsonisms, and no association with striatal DAT binding, it would question the rational use of GR as part of the clinical examination of a patient with suspected PD. This evidence concerns the gene SLC6A3 and Parkinson disease.